Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
I don’t know whether that’s a quote from something or fresh off the dome but that’s an absolute banger of a line.
It is a fresh assembly of deeper thoughts by smarter people. So it’s just an internet comment essentially.